Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs NV-5138 (Primary)
- Indications Depressive disorders
- Focus Adverse reactions
- Sponsors Navitor Pharmaceuticals
- 12 Sep 2019 According to a Navitor Pharmaceuticals media release, the company plans to present additional data from the Phase 1 program (three studies 001, 002, 003) at upcoming medical meetings this fall.
- 12 Sep 2019 Results presented in a Navitor Pharmaceuticals media release.
- 07 Jul 2019 Status changed from recruiting to completed.